A wealth of knowledge has been brought back to New Zealand by two Breast Cancer Aotearoa Coalition representatives following the Breast Cancer Trials Australia New Zealand annual scientific meeting
Recent international developments in breast cancer medicine approvals emphasise the need for a much broader range of medicines in New Zealand.
Breast Cancer Aotearoa Coalition and Breast Cancer Foundation NZ have made a strongly worded and evidence-based joint submission to PHARMAC requesting that funding for Perjeta (pertuzumab) be exten
Important research released 21 June shows huge disparities in breast cancer screening, treatment and outcomes for Māori and Pasifika women in New Zealand.
BCAC says a new report highlights how desperately poor access to new and innovative medicines is in New Zealand.
BCAC committee member, Louise Malone, attended the San Antonio Breast Cancer Symposium in December 2017 and gives us an update on the latest cutting-edge research into new targeted immunoth
The Breast Cancer Aotearoa Coalition (BCAC) is pushing for the chemotherapy drug, Abraxane, to be publicly funded for women with advanced breast cancer.
Metavivors NZ members were in full force at BCAC’s Annual General Meeting at Domain Lodge in Auckland recently.
BCAC is pushing for breakthrough breast cancer drug, Kadcyla, to be publicly funded in New Zealand after a “monumental u-turn” in the UK which has seen the drug funded there.
New guidelines in the UK recommend that healthy post-menopausal women with a familial risk of developing breast cancer be prescribed the medicine anastrazole in a bid to help ward off the disease.
